Mocravimod is under clinical development by Kyorin Pharmaceutical and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Mocravimod’s likelihood of approval (LoA) and phase transition for Hematopoietic Stem Cell Transplantation took place on 02 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mocravimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
KRP-203 is under development for the treatment of the autoimmune diseases like ulcerative colitis, subacute cutaneous lupus erythematosus, Acute Myeloid Leukemia (AML) and Crohn’s disease and hematopoietic stem cell transplantation. The drug candidate is an orally administered immunosuppressant that acts by targeting S1P receptor. It was also under development for the treatment of the subacute cutaneous lupus erythematosus and ulcerative colitis and also for inflammatory bowel disease in Japan.
It was under development for the treatment of autoimmune diseases, inflammatory bowel disease, graft versus host disease (transplantation) and Crohn's disease.
Kyorin Pharmaceutical overview
Kyorin Pharmaceutical (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines. It offers Ketas, a phosphodiesterase inhibitor agent for treating bronchial asthma and cerebro-vascular disorders. Kyorin provides Kipres, a bronchial asthma and allergic rhinitis therapeutic drug; and Pentasa an agent for ulcerative colitis and chrohn’s disease. The company’s various ethical drugs include lasvic, mucodyne, pentasa, uritos, flutiform, desalex, nasonex and beova and lasvic. It offers consumer healthcare products such as over-the-counter drugs. Kyorin provides Milton brand to offer baby bottle disinfectant products. The company collaborates with other companies to develop new medicine. It has operations in the US and Germany. Kyorin is headquartered in Chiyoda, Tokyo, Japan.
Quick View Mocravimod LOA Data
|Highest Development Stage|